AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02793661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Hydration protocol following ESC Guidelines 2014
Study NCT03099473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular electroacupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
Study NCT03099473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular acupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
Study NCT03099473 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
Study NCT01101451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01101451 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo radiotherapy
Study NCT01101451 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo radiotherapy
Study NCT01101451 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo radiotherapy
Study NCT01101451 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo radiotherapy
Study NCT01101451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00262301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human C1 inhibitor
Description: IV
Study NCT00262301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study NCT01101451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01101451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01101451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01101451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01101451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03246607 — intervention group
Intervention type: DEVICE
Intervention: MicroEye & ContinuMon
Description: Continuous intravascular glucose monitoring using MicroEye/ContinuMon system, peripherally inserted via a peripheral venous catheter.
Study NCT00002593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV as described in Arm Description
Study NCT00002593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV as described in Arm description.
Study NCT04290013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norethisterone acetate
Description: norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.
Study NCT04290013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid tablets
Description: tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.
Study NCT02058875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic®
Study NCT02058875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic®
Study NCT02058875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoral®
Study NCT00002593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levamisole hydrochloride
Description: Given as described in arm description
Study NCT02058875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cellcept®
Study NCT02058875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT01823133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin only
Description: gemigliptin 50mg qd on day 1\~7
Study NCT01823133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin only
Description: rosuvastatin 20mg qd on day 1\~7
Study NCT01823133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin and rosuvastatin
Description: gemigliptin 50mg, rosuvastatin 20mg qd on day 1\~7
Study NCT00677391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibutramine
Description: Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.
Study NCT00677391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, once daily
Study NCT03565315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB095-00-AB (10E8VLS)
Description: 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.
Study NCT03565315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB075-00-AB (VRC07-523LS)
Description: VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
Study NCT04162444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Physical examination
Description: A physical examination is a routine screening procedure used to investigate a patient's symptoms or complaints. It consists of a series of questions regarding patient medical history followed by an examination of the symptoms to determine the correct diagnosis and treatment plan.
Study NCT04162444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Ross Classification for Heart Failure in Children
Description: The assessment is performed by pediatric cardiologist according to the classic Ross scale. One of the 4 classes of chronic heart failure is registered.
Study NCT04162444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Aristotle score
Description: Surgical risks will be assessed by the ARISTOTLE score developed specially for the task. The calculation will be performed online, available from http://www.aristotleinstitute.org.
Study NCT04162444 — intervention group
Intervention type: OTHER
Intervention: Assessment of administered specific therapy
Description: The data will be registered as groups of administered medicines:~* Antiplatelet agents~* Loop diuretics~* Potassium-sparing diuretics~* Angiotensin-converting enzyme inhibitors
Study NCT04162444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multispiral computed tomography/3D echocardiography
Description: All patients enrolled in the study should be routinely examined with multispiral computed tomography (MS-CT) or 3D-echo before surgery and 3 years later. As a result, a 3D aortic root reconstruction will be made to assess its size and anatomy and subsequently build a 3D soft model for surgery imitation.~At the study onset, we plan to perform MS-CT, then 3D-echo. If the correlation resulting from 3D-echo and the actual sizes will be high, the isolated 3D-echo will be preferred in the future.~If none of the methods is available, the patients will not be enrolled in the study.~The following data will be registered for further analysis:~* Perimeter of the aortic valve~* Diameter of the aortic valve at sinuses level~* Height of the aortic sinuses~* Morphology of the aortic valve
Study NCT04162444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic and transesophageal echocardiography
Description: Transthoracic echocardiography is carried out at baseline, at discharge and then annually. It is performed in order to assess the contractile function of the heart and hemodynamic characteristics of the aortic valve and its autopericardium graft.~Transesophageal echocardiography is carried out directly after the withdrawal of the artificial circulation when performing augmentation of the aortic valve with autopericardium in order to asses hemodynamic characteristics of the aortic neo-valve.
Study NCT04162444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 12-lead electrocardiogram
Description: Registering 12-lead electrocardiogram (ECG) is used as a tool for assessment of the regularity of the heart rhythm as well as screening and predictive tool for assessment of fibrosis and hypertrophy processes in the myocardium. The following data will be registered:~* Heart rate~* Sinus rhythm (yes/no)~* Positive R wave in leads V5-6~* Angle α less than 0~* Presence/absence of abnormal Q wave~* Presence/absence of ST-segment depression in precordial leads
Study NCT04519931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress ball
Description: The stress ball is a toy, usually no larger than 7 cm. It is used to relieve stress and muscle tension. Stress ball is one of the cognitive and behavioral therapy methods used in pain control. Stress ball is used as a method of diverting attention during painful procedures. It appears to reduce pain and anxiety.
Study NCT03648710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Community Health Worker
Description: Participants will be communicating with their CHWs on a weekly basis, which is consistent with other successful community health worker protocols with published efficacy. Community Health Workers will be peers with sickle cell disease, who have successfully transitioned and are under 30 years of age.
Study NCT03648710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health
Description: A mobile health application created as a resource for young adults transitioning.
Study NCT02169310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: There is no study intervention for Experiment 1. The study intervention for Experiment 2 is tDCS. tDCS is a non-invasive brain stimulation technique that uses electrodes attached to the scalp to deliver very low intensity direct current to the brain. This intervention has been demonstrated to result in neuromodulatory effects.
Study NCT02169310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: There is no study intervention for Experiment 1. The study intervention for Experiment 2 is tDCS. tDCS is a non-invasive brain stimulation technique that uses electrodes attached to the scalp to deliver very low intensity direct current to the brain. This intervention has been demonstrated to result in neuromodulatory effects.
Study NCT02169310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] Raclopride
Description: \[11C\] Raclopride is administered under an IND 054135. This IND is sponsored by the NIH Clinical Center and \[11C\] Raclopride is dispensed by the NIH PET Department. Quality Assurance for Radioactive Drug: \[11C\] Raclopride, is assayed for radiochemical purity under the supervision of the NIH PET Department prior to dispensing the drug for administration. Given that IND PET drugs manufactured at the NIH PET Department are used in a single site and that there is no intent for their commercialization, submission of IBs has not been required by FDA for any of the NIH Office of Research Support and Compliance-sponsored IND applications.
Study NCT00752414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376 (Levofloxacin solution for Inhalation)
Description: Daily for 5 days
Study NCT00752414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same frequency as MP-376
Study NCT05121961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacroiliac intra-articular injection
Description: CT guided injection of platelet-rich plasma versus steroid/anesthetic into the sacroiliac joint
Study NCT05121961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacroiliac intra-articular injection
Description: CT guided injection of platelet-rich plasma versus steroid/anesthetic into the sacroiliac joint
Study NCT00444106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-mefloquine
Study NCT00444106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atovaquone-proguanil
Study NCT00444106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Study NCT02115113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
Study NCT02059421 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: - Therapy session administered by a clinical psychologist using web-based video conferencing software.~Therapy sessions will include:~* Sleep restriction therapy~* Stimulus control instructions~* Sleep hygiene education
Study NCT02059421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Johrei therapy
Description: * Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence.~* Therapy sessions will consist of 3 sessions per week lasting 30 minutes each.~* Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance.~* Therapy will be administered without physical contact.~* During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient.
Study NCT02115113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
Study NCT02115113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
Study NCT03023345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave trans rectal focal treatment
Description: Microwave trans-rectal ablation of the prostatic index tumor using MRI-transrectal ultrasound image registration
Study NCT00011583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy
Description: 1 hour/day of mechanically-assisted upper limb therapy
Study NCT00011583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional therapy
Description: 1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
Study NCT02366325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO-018B
Study NCT02606630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-555
Description: ABT-555 will be administered on Visit 4 in Part 2 only
Study NCT03668964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B2
Description: One capsule of 75 mg Vitamin B2 once a day for 4 weeks
Study NCT03668964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: One capsule of 500 mg Vitamin C once a day for 4 weeks
Study NCT03668964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B2 + C
Description: One capsule of of 75 mg Vitamin B2 plus 500 mg Vitamin C once a day for 4 weeks
Study NCT03668964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: One capsule of 250 µg Vitamin A once a day for 4 weeks
Study NCT03668964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: One capsule of 60 µg Vitamin D3 once a day for 4 weeks
Study NCT03668964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: One capsule of 100 mg Vitamin E once a day for 4 weeks
Study NCT03668964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of 575 mg microcrystalline cellulose once a day for 4 weeks
Study NCT01625234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I: X-396 (ensartinib)
Description: Oral, ALK inhibitor
Study NCT01625234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II: X-396 (ensartinib)
Description: Expanded Cohort
Study NCT00566072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instructions and coaching
Description: instructions and coaching or no intervention on the use and intake of ganciclovir
Study NCT02550015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Uphill treadmill walking
Study NCT02550015 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: General information
Description: Standard care
Study NCT02789852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthosis
Description: use orthosis
Study NCT04326062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Main Study
Description: The pharmacist will participate in the management of repeat prescribing and undertake medication reviews (which will address high risk prescribing and potentially inappropriate prescribing, deprescribing and cost-effective and generic prescribing) with adult patients. Pharmacists will also provide prescribing advice regarding the use of preferred drugs, undertake clinical audits, join practice team meetings and facilitate practice-based education. Throughout the six-month intervention period, anonymised practice-level medication (e.g. medication changes) and cost data will be collected.
Study NCT04326062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROM Study
Description: For this, a sub-set of patients (n=200) aged ≥65 years on ≥10 repeat medicines will be recruited and invited to a medication review with the pharmacist. PROMs and healthcare utilisation data will be collected using patient questionnaires and a six-week follow-up review with these patients will also be conducted.
Study NCT02224534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
Study NCT03761472 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid injection
Description: Hyaluronic acid 48 mg 2.0% in 2.4 ml solution
Study NCT03761472 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich plasma injection
Description: Platelet-rich plasma injection 5ml
Study NCT02115113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
Study NCT02224534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
Study NCT02278640 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Harmonic ACE®+7 Shears
Description: Vessel/pedicle sealing performance assessed for transection and sealing of the of the uterine vasculature.
Study NCT03041935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ilioinguinal/iliohypogastric nerve block
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal-epidural nerve block
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: See arm description
Study NCT02912598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mallinckrodt™ Endobronchial Tube
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: See arm description
Study NCT03098368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: See arm description